Sandbox Turky2: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 11: Line 11:
|- align="center"
|- align="center"
|'''Campylobacter species''' || [[Erythromycin]], 500 mg b.i.d. 3 5 dc  || Same (but may require prolonged treatment)
|'''Campylobacter species''' || [[Erythromycin]], 500 mg b.i.d. 3 5 dc  || Same (but may require prolonged treatment)
|}

Revision as of 13:27, 1 June 2015


GI infection
Pathogen Immunocompetent patients Immunocompromised patients
Shigella species TMP-SMZ, 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. 3 3 d (if susceptiblea ) or fluoroquinolone (e.g., 300 mg ofloxacin, 400 mg norfloxacin, or 500 mg ciprofloxacin b.i.d. 3 3 d); nalidixic acid, 55 mg/kg/d (pediatric) or 1 g/d (adults) 3 5 d [220] or ceftriaxone azithromycin 3 7–10 d
Non-typhi species of Salmonella Not recommended routinely, but if severe or patient is !6 mo or 150 y old or has prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia, TMP-SMZ (if susceptible) or fluoroquinolone as above, b.i.d. 3 5–7 d; ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses 14 d (or longer if relapsing)
Campylobacter species Erythromycin, 500 mg b.i.d. 3 5 dc Same (but may require prolonged treatment)